Manufacturing

The Carlsbad facility brings end-to-end viral vector solutions and aseptic fill-finish capabilities to Lonza, catering specifically to the burgeoning cell and gene therapy market. This strategic acquisition of five specialized contract development and manufacturing organization (CDMO) sites from

Institutional investors now manage portfolios by treating inadequate environmental, social, and governance strategies as material financial liabilities rather than mere corporate social responsibility gestures. This seismic shift marks the end of an era where pharmaceutical companies could rely on

Siloed data across quality, manufacturing, and post-market surveillance prevents manufacturers from seeing the cross-functional impacts that regulatory AI tools now identify instantly. The medical device industry is currently navigating a period of unprecedented transformation, where the

A dual-sourcing strategy ensures that the pursuit of environmental milestones does not compromise the security of the supply chain for essential medical treatments. As global healthcare systems face unprecedented demand, the pharmaceutical industry is increasingly pressured to harmonize life-saving

Ethiopia's strategy reflects a broader continental trend toward health security, where local production is viewed as the only viable path to effective public health response. By 2030, the nation intends to transition from a major importer of medical goods to a self-reliant manufacturing powerhouse,

The global pharmaceutical landscape is navigating an era where ecological accountability has transitioned from a boardroom aspiration to a non-negotiable operational mandate for every stakeholder involved. Operating continuous utility systems to maintain cleanroom environments represents a